<html><head><style>div {border : red solid 0.5px}</style><style>span {border : blue dotted 0.5px}</style></head><body><div left="34.02" right="58.06" top="760.96"><span x0="34.02" y0="760.96" x1="58.06" style="x0: 34.02; x1: 39.58; y0: 760.96; y1: 770.96; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">98.  </span><span x0="55.28" y0="760.96" x1="547.21" style="x0: 55.28; x1: 61.02; y0: 760.96; y1: 770.96; width: 5.74; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">The major philanthropic foundations have been playing a critical role in supporting investments with high-risk and/or low-commercial incentives</span><span x0="258.79" y0="747.46" x1="547.03" style="x0: 258.79; x1: 261.57; y0: 747.46; y1: 757.46; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">. However, the major scale-up of research on infectious diseases and countermeasures needed will have to involve stronger partnerships between the public, private and philanthropic sectors, nationally and globally.</span></div><div left="55.28" right="134.27" top="694.46"><span x0="55.28" y0="694.46" x1="134.27" style="x0: 55.28; x1: 60.47; y0: 694.46; y1: 704.46; width: 5.19; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">a. These include </span><span x0="133.71" y0="694.46" x1="547.24" style="x0: 133.71; x1: 139.45; y0: 694.46; y1: 704.46; width: 5.74; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">early-stage investments, e.g. the search for vaccines and therapeutics that can provide broad protection against a range of pathogens</span><span x0="295.49" y0="681.46" x1="547.03" style="x0: 295.49; x1: 298.27; y0: 681.46; y1: 691.46; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">; and interventions that can address the rising threat of drug resistance. </span></div><div left="55.28" right="547.06" top="642.46"><span x0="55.28" y0="642.46" x1="547.06" style="x0: 55.28; x1: 61.39; y0: 642.46; y1: 652.46; width: 6.11; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">b. They could also be strong partners in supporting research for interventions where commercial interest is low, including many ongoing regional epidemics for which global demand is weak. </span></div><div left="34.02" right="546.98" top="602.66"><span x0="34.02" y0="602.66" x1="546.98" style="x0: 34.02; x1: 39.58; y0: 602.66; y1: 612.66; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">99.  Governments and international organizations must seek to broaden the base, incentivize and leverage philanthropic foundations that are engaged in supporting discovery science and R&amp;D that contribute to national health resilience and pandemic PPR. </span></div><div left="55.28" right="546.99" top="549.66"><span x0="55.28" y0="549.66" x1="546.99" style="x0: 55.28; x1: 60.47; y0: 549.66; y1: 559.66; width: 5.19; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">a. CEPI is an example of a philanthropy inspired, public-private partnership working at the interface between science, R&amp;D, and manufacturing for global public goods.</span></div><div left="34.02" right="58.24" top="509.86"><span x0="34.02" y0="509.86" x1="58.24" style="x0: 34.02; x1: 39.58; y0: 509.86; y1: 519.86; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">100.  </span><span x0="55.28" y0="509.86" x1="547.21" style="x0: 55.28; x1: 62.87; y0: 509.86; y1: 519.86; width: 7.59; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">De-risking by philanthropic and official funders can potentially mobilize significant resources from patient capital, including pension funds and sovereign wealth funds, for R&amp;D and other longer-term investments.</span></div><div left="55.28" right="546.99" top="470.36"><span x0="55.28" y0="470.36" x1="546.99" style="x0: 55.28; x1: 60.47; y0: 470.36; y1: 480.36; width: 5.19; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">a. These investments may have high social returns but will often be beyond the risk appetite of institutional investors. Public and philanthropic participation can bridge this risk gap.</span></div><div left="55.28" right="547.04" top="431.36"><span x0="55.28" y0="431.36" x1="547.04" style="x0: 55.28; x1: 61.39; y0: 431.36; y1: 441.36; width: 6.11; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">b. For instance, a project to develop a new tuberculosis vaccine could be organized with commercial discipline, while partly financed by philanthropy, and with official entities contributing to de-risk the project.</span></div><div left="34.02" right="442.05" top="372.4"><span x0="34.02" y0="372.4" x1="442.05" style="x0: 34.02; x1: 39.94; y0: 372.4; y1: 392.4; width: 5.92; font-size: 20.0; fill: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Heavy;">(9)  Develop insurance solutions for adverse compensation events associated with use of medical countermeasures</span></div><div left="34.02" right="58.06" top="290.99"><span x0="34.02" y0="290.99" x1="58.06" style="x0: 34.02; x1: 39.58; y0: 290.99; y1: 300.99; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">101.  </span><span x0="55.28" y0="290.99" x1="547.31" style="x0: 55.28; x1: 61.02; y0: 290.99; y1: 300.99; width: 5.74; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">The best insurance for the world against pandemic risks is to invest in global public goods for pandemic prevention and preparedness, as we have laid out in this report</span><span x0="370.4" y0="277.49" x1="547.04" style="x0: 370.4; x1: 373.18; y0: 277.49; y1: 287.49; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">. The investments required to avoid a pandemic amount to a miniscule proportion of the financial costs to governments in a pandemic, not counting the costs of human lives lost, long-term health impairment and broader economic and social costs.</span></div><div left="34.02" right="58.06" top="223.69"><span x0="34.02" y0="223.69" x1="58.06" style="x0: 34.02; x1: 39.58; y0: 223.69; y1: 233.69; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">102.  </span><span x0="55.28" y0="223.69" x1="547.23" style="x0: 55.28; x1: 58.24; y0: 223.69; y1: 233.69; width: 2.96; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">Insurance solutions should also be developed to cover adverse effects associated with medical countermeasures</span><span x0="137.71" y0="210.19" x1="143.27" style="x0: 137.71; x1: 140.49; y0: 210.19; y1: 220.19; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">. </span></div><div left="55.28" right="547.07" top="184.19"><span x0="55.28" y0="184.19" x1="547.07" style="x0: 55.28; x1: 60.47; y0: 184.19; y1: 194.19; width: 5.19; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">a. Where vaccines and treatments are developed and regulated using emergency authorization, manufacturers are not generally able to obtain insurance in the usual way that would happen if a product has been licensed under non-emergency arrangements.</span></div><div left="55.28" right="509.15" top="132.19"><span x0="55.28" y0="132.19" x1="509.15" style="x0: 55.28; x1: 61.39; y0: 132.19; y1: 142.19; width: 6.11; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">b. To address this constraint during the COVID-19 pandemic, COVAX used donor funds to enable a </span><span x0="508.59" y0="132.19" x1="547.18" style="x0: 508.59; x1: 514.15; y0: 132.19; y1: 142.19; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">vaccine injury compensation program through a contract with private insurers </span><span x0="430.37" y0="119.19" x1="546.89" style="x0: 430.37; x1: 440.37; y0: 119.19; y1: 129.19; width: 10.0; font-size: 10.0; fill: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">&#8212; the first of its nature on an international scale. The COVAX No-Fault Compensation Program offers eligible people in 92 LICs and LMICs compensation for rare but serious adverse effects associated with COVID-19 vaccines distributed through COVAX, thereby protecting participating governments and providers as well as vaccine manufacturers from liability. However, this scheme only applies to vaccines acquired through </span></div></body></html>